Sánchez-Delgado J, et al. - Researchers conducted this study to examine the overall survival (OS) and prognostic factors of patients with hepatocellular carcinoma (HCC) treated with drug-eluting bead transarterial chemoembolization (DEB-TACE). They recorded patients’ clinical course from January 2005 to July 2014. It was noted that the median OS was 22.8. OS was 23.87 and 26.89 after censoring for ascites and more than one nodule. They observed that the risk of death declined by 22.3% with the number of DEB-TACE sessions and raised by 25.9% with a higher Child-Pugh score. Overall, 61.2% of the cohort had an assessment for retreatment with TACE score (ART score) between 0 and 1.5. No statistical differences were found in OS between cohort groups with ART of 0–1.5 and at least 2.5. The study findings confirm the safety and effectiveness of DEB-TACE in patients with HCC and the value of some prognostic factors for patient survival.